Trial Profile
A Phase I Dose-Escalation Study of NMS-1116354 in Adult Patients With Advanced Solid Tumors.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 11 Sep 2012
Price :
$35
*
At a glance
- Drugs NMS 1116354 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Registrational
- 01 Sep 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov. (NCT01016327)
- 01 Sep 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov. (NCT01016327)
- 25 Mar 2010 Planned end date changed from 1 Sep 2010 to 1 Mar 2011 as reported by ClinicalTrials.gov (NCT01092052).